Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF – Get Free Report) is anticipated to announce its resultson Thursday, March 19th. Analysts expect the company to announce earnings of $0.8570 per share and revenue of $769.7510 million for the quarter.
Recordati Industria Chimica E Farmaceutica Stock Performance
Shares of RCDTF stock opened at $56.95 on Thursday. The business has a fifty day moving average of $63.57 and a 200 day moving average of $64.79. Recordati Industria Chimica E Farmaceutica has a 1 year low of $49.00 and a 1 year high of $65.44. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.16 and a current ratio of 1.64.
Analyst Upgrades and Downgrades
A number of research firms recently commented on RCDTF. Barclays raised Recordati Industria Chimica E Farmaceutica from a “strong sell” rating to a “hold” rating in a report on Thursday, February 12th. Kepler Capital Markets raised shares of Recordati Industria Chimica E Farmaceutica from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 3rd. Two analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy”.
About Recordati Industria Chimica E Farmaceutica
Recordati Industria Chimica e Farmaceutica is an Italy‐based international pharmaceutical company engaged in the research, development, manufacturing and commercialization of therapeutic products. Established in 1926, the company has built a diversified portfolio that includes proprietary drugs, generics and orphan medicines, with a particular emphasis on treatments for rare diseases. Recordati’s product range spans cardiovascular, urology, endocrinology, dermatology and oncology therapies, as well as specialized formulations for genetic and metabolic disorders.
The company’s historical roots date back nearly a century, when it began as a family‐owned enterprise in Milan.
See Also
- Five stocks we like better than Recordati Industria Chimica E Farmaceutica
- What a Former CIA Agent Knows About the Coming Collapse
- I tried out Elon Musk’s new AI tech — it floored me
- “I just bought 10,000 shares of a $5 stock…”
- The Next Commodity Crunch (bigger than oil?)
- Nvidia CEO Issues Bold Tesla Call
Receive News & Ratings for Recordati Industria Chimica E Farmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recordati Industria Chimica E Farmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
